EnteroBiotix is at the forefront of developing innovative gut therapeutics, focusing on full-spectrum microbiome solutions. Their core technology revolves around the Intestinal Microbial Transfer (IMT) therapies, which aim to restore and enhance gut microbial ecology to prevent and treat diseases. This approach utilizes microorganisms sourced from healthy donors, ensuring a diverse and stable microbial ecosystem. EnteroBiotix's proprietary drying technology and sophisticated analytical toolkit allow for the precise characterization and consistent formulation of their products, which are delivered in stable oral capsules. This unique formulation not only maintains the integrity of the anaerobic microbiota but also enhances the therapeutic potential of the microbiome.

The company is currently advancing its clinical pipeline, with promising results from Phase 1b trials for its lead product, EBX-102, in liver cirrhosis, demonstrating safety and potential efficacy. EnteroBiotix's commitment to addressing unmet medical needs in gastrointestinal and hepatic diseases is evident in their ongoing Phase 2 studies for conditions like irritable bowel syndrome (IBS) and their collaboration with Imperial College London. By leveraging their advanced manufacturing capabilities and a controlled supply chain, EnteroBiotix aims to deliver high-quality microbiome therapeutics that not only treat symptoms but also restore the foundational balance of gut health.

United Kingdom

EnteroBiotix is a leading microbiome therapeutics platform company that is focussed on transforming the standard of care for patients battling debilitating diseases and infections linked to disruptions to structure and function of the gut microbiome.

Digestive System Diseases

Liver Diseases

Phoenix House, Phoenix Crescent, Strathclyde Business Park, Bellshill, Glasgow ML4 3NJ

EnteroBiotix

Company Details